Drug intelligence / Profile preview

LCB58A

Development stage: Preclinical
Lead developer: LigaChem Biosciences, Inc.
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LCB58A is an investigational **antibody-drug conjugate (ADC)** designed to target **carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)**, which is commonly overexpressed in several carcinomas. The ADC consists of a monoclonal antibody specific for CEACAM5 linked to a cytotoxic payload, enabling targeted delivery of the toxic agent to CEACAM5-expressing tumor cells. Developed by LigaChem Biosciences, LCB58A is being evaluated for efficacy and safety in clinical trials for cancer indications, including non-small cell lung cancer and other solid tumors that express CEACAM5[4].

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on LCB58A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LCB58A.

Explore the full profile